Fanconi anemia is a rare genetic disease in which essential DNA repair pathway genes are mutated, disrupting the DNA damage response. Patients with Fanconi anemia experience hematological complications, including bone marrow failure, and are predisposed to cancer. The only curative therapy for the hematological symptoms of Fanconi anemia is an allogeneic hematopoietic stem cell transplant, in which a patient receives healthy stem cells from a donor. While this may cure or prevent some of the diseases complications, stem cell transplantation can cause additional difficulties, including graft-versus-host disease (GvHD) and exacerbated cancer risk.1
There is growing interest in applying genome editing technologies like CRISPR-Cas9 to correct Fanconi anemia mutations in patient-derived cells for autologous transplants, in which corrected stem cells are given back to the patient. However, this disease poses a unique challenge: How do you apply a genome editing technique in cells that are particularly sensitive to DNA damage? Fanconi anemia cells cannot resolve the double-strand breaks that conventional CRISPR-Cas9 gene editing creates in the target DNA, which prevents researchers from effectively correcting disease-causing mutations with this method.
In a study published in International Journal of Molecular Science, a research team at the University of Minnesota led by Branden Moriarity and Beau Webber used Cas9-based tools called base editors (BEs) to edit genes in Fanconi anemia patient-derived cells without inducing double-strand DNA damage.2 BEs are fusion proteins made of a Cas9 enzyme that cleaves target DNA (nCas9) and a deaminase that converts cytidine to uridine (cytosine base editor, CBE) or adenosine to inosine (adenosine base editor, ABE). During DNA replication or repair, sites targeted by a BE are rewritten as thymine in the case of CBEs, or guanine with ABEs.
Although base editors do not induce double-strand breaks, they still nick the DNA and trigger a DNA repair response. Because of this, the researchers first examined if CBEs and ABEs would work on non-Fanconi anemia genes in patient-derived cells. There was that mystery, you know, because [Fanconi anemia patient cells are] DNA repair deficient. So we weren't surewe thought maybe it would work, but not as well as a normal cell. But indeed, it works on the same level, basically. So that was pretty exciting, Moriarity explained.
The research team then demonstrated that CBEs and ABEs can correct Fanconi anemia-causing mutations in the FANCA gene in primary patient fibroblast and lymphoblastoid cell lines. Base editing restored FANCA protein expression and improved the ability of the patient-derived cells to grow in the presence of a DNA damaging chemical. Additionally, in culture, fibroblasts with corrected FANCA mutations outgrew cells in which the base editing failed. Finally, the researchers assessed if BEs could correct mutations in different Fanconi anemia genes. Using an algorithm, they predicted that most Fanconi anemia mutations were correctable either by BEs or by another nCas9-fusion technology called prime editing (PE), which is capable of large genetic insertions and deletions.
This work comes on the heels of a preprint from another research group at The Centre for Energy, Environmental and Technological Research and ETH Zurich, who investigated ABEs in patient blood cell lines. This group also effectively targeted Fanconi anemia genes with BE technology, and their investigation went one step further: they corrected mutations in patient-derived hematopoietic stem cells.3This was something that Moriarity and Webber were unable to dobecause the disease is a bone marrow failure syndrome, these cells are scarce. Basically, these patients do not have stem cells, explains Annarita Miccio, a senior researcher and lab director at Institute Imagine of Paris Cit University, who was not involved in either study. These are very challenging experiments, and more than the experiments, the challenge of [treating] Fanconi anemia is exactly thatthe number of cells.
Despite this challenge, the researchers have laid the groundwork for genome editing as a treatment approach in Fanconi anemia, without the need for double-strand DNA breaks. I think the study we did is a good, solid proof of concept, and sets the stage for the next steps, but certainly, it's not the end of the story, said Webber.
References
Read the original:
A CRISPR Alternative for Correcting Mutations That Sensitize Cells to DNA Damage - The Scientist
- Stem cell treatment after spinal cord injury: The next steps - Mayo Clinic - December 18th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 13th, 2022
- A history of blood cancer treatment - - pharmaphorum - September 16th, 2022
- What Are Zombie Cells? Here's How They Impact Aging - Prevention Magazine - September 8th, 2022
- ThreeSixty Journalism: Be The Match works to build equity in access to bone marrow and cord blood transplants - St. Paul Pioneer Press - September 8th, 2022
- Zhang and colleagues win an $11.2 million NIH program project grant (PPG) - News - University of Alabama at Birmingham - August 22nd, 2022
- Kyle Vining: Appointment to Faculty of Penn Dental Medicine and Penn School of Engineering and Applied Science - University of Pennsylvania - August 22nd, 2022
- Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 - Business Wire - August 14th, 2022
- Engineers develop new tool that will allow for more personalized cell therapies - UMN News - July 27th, 2022
- University of Minnesota scientist responds to fraud allegations in Alzheimer's research - Star Tribune - July 27th, 2022
- Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes - UCSF - July 27th, 2022
- TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts - GuruFocus.com - July 11th, 2022
- Witt Wolfpack: Family works out fundraising and awareness after La Jollan's ALS diagnosis - La Jolla Light - July 11th, 2022
- Pluripotent stem cellderived NK cells with high-affinity noncleavable ... - July 3rd, 2022
- Life-saving lecture: Auburn student uses lessons from class to help discover father's brain tumor - Office of Communications and Marketing - June 22nd, 2022
- Bluebird's future in balance as FDA weighs gene therapy approvals - BioPharma Dive - June 13th, 2022
- Be the Match is looking for more ethnically diverse donors to help patients with blood cancers and diseases - KARE11.com - June 4th, 2022
- Minnesota woman reunites with teenager she saved through Be The Match transplant - KSTP - April 19th, 2022
- Induced Pluripotent Stem Cells and Their Potential for ... - November 22nd, 2021
- Cells or drugs? The race to regenerate the heart - Scientific American - November 8th, 2021
- Four-year-old with rare disease finally gets historic gene therapy treatment - KARE11.com - October 5th, 2021
- Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors - Stockhouse - October 5th, 2021
- EDITORIAL: The need is vast. Consider becoming an organ donor. - Yahoo News - August 18th, 2021
- Our View: The need is vast. Consider becoming an organ donor. - PostBulletin.com - August 18th, 2021
- Negrin Shines Light on the Orca-T Story in GVHD - OncLive - December 11th, 2020
- COVID-19 and the trials of treatment | News, Sports, Jobs - Escanaba Daily Press - October 16th, 2020
- NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank - Watauga Democrat - October 7th, 2020
- Berks County's first STEM-themed attraction opens, delights visitors young and old - Reading Eagle - October 7th, 2020
- Coronavirus Thursday update: UMN announces new stem cell ... - August 16th, 2020
- University of Minnesota launches stem cell trial against ... - August 16th, 2020
- University of Minnesota launches stem cell trial against severe COVID-19 - Minneapolis Star Tribune - August 16th, 2020
- Biotechnology Could Change the Cattle Industry. Will It Succeed? - Singularity Hub - August 16th, 2020
- Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update - Yahoo Finance - April 4th, 2020
- A word for those risking their lives amid the coronavirus crisis: Thanks - TwinCities.com-Pioneer Press - April 4th, 2020
- Coronavirus is similar to SARS and causes infection through a heart regulating enzyme: Study - International Business Times, Singapore Edition - February 4th, 2020
- Why Sangamo Therapeutics Stock Sank Today - The Motley Fool - December 13th, 2019
- Hoeven's bill supports alternative therapy for veterans with PTSD, traumatic brain injury - Ripon Advance - October 1st, 2019
- Stem-cell treatment gives two brothers a future ... - March 3rd, 2019
- The Promise of Stem Cells | Stem Cell Institute ... - August 29th, 2018
- 2018 Regenerative Medicine Minnesota Research Awards - August 17th, 2018
- FDA cracks down on stem cell clinics - CNN - August 29th, 2017
- Mayo Clinic, University of Minnesota develop 'robocop' stem cells to fight cancer - Minneapolis Star Tribune - August 24th, 2017
- Cowboy Up Ride Against Cancer - Wahpeton Daily News - August 24th, 2017
- Cargill invests in 'clean meat' start-up - KARE - August 24th, 2017
- Stem-cell clinics are using a federal website as a marketing tool for unproven treatments, U of M bioethicist says - MinnPost - July 30th, 2017
- More than 60 US clinics have sold unproven stem cell therapies for heart failure - New York Post - July 30th, 2017
- Stemonix, a stem cell research firm, wins Minnesota Cup ... - November 27th, 2016
- Minnesotas Funding of Stem Cell Research Echoes Trend ... - October 29th, 2016
- Stem cell research Experts@Minnesota - October 18th, 2016
- Stem Cell FAQs - Minnesota Regenerative Medicine - October 7th, 2016
- Minnesota invests in regenerative medicine - Health Talk - October 7th, 2016
- Minnesota to resume umbilical cord blood donations ... - September 20th, 2016
- STEM Programs - Minnesota Zoo - September 5th, 2016
- Stem Cell Treatment - Minnesota Regenerative Medicine - August 18th, 2016
- Home - Minnesota Regenerative Medicine - August 18th, 2016
- Multipotent vs. pluripotent stem cells - Pathology Student - October 19th, 2015
- 2. Bone Marrow (Hematopoietic) Stem Cells [Stem Cell ... - October 19th, 2015
- Minnesota Man With ALS Hopes Stem Cells Save His Life ... - July 2nd, 2015
- Graduate Programs - MED - Stem Cell Institute, University ... - April 26th, 2015
- Atsushi Asakura, Ph.D. - MED - Stem Cell Institute ... - March 18th, 2015
- Bioelectricity Plays Key Role in Brain Development & Repair - March 13th, 2015
- Jakub Tolar, M.D., Ph.D. - MED - Stem Cell Institute ... - February 24th, 2015
- Stem Cell Web Focus - Nature Publishing Group : science ... - February 3rd, 2015
- Family: Experimental stem-cell treatment does wonders for Gordie Howe - December 20th, 2014
- Childrens hospital gets $25M - December 16th, 2014
- Stem Cell Malaysia Blog - December 12th, 2014
- Reduction of germ cells yields more zebrafish males - December 4th, 2014
- Cardio3 BioSciences Announces the Nomination of Three Co-Principal Investigators for Its CHART-2 Phase III Clinical ... - November 28th, 2014
- Mayo Clinic Researchers Identify First Steps in Formation of Pancreatic Cancer - November 10th, 2014
- Anti-Cancer Drug Effective Against Common Stem Cell Transplant Complication - October 24th, 2014
- $25M gift prompts University pediatric hospital name change - October 16th, 2014
- Becoming a blood stem cell or bone marrow donor ... - October 3rd, 2014
- New heart built with stem cells - YouTube - September 27th, 2014
- Cancer Survivor Saved by Measles Virus Raises Funds for Expanded Trial - September 12th, 2014
- Researchers find animal model for understudied type of muscular dystrophy - August 30th, 2014
- Minnesota Stem Cell Therapy | Stem Cell Treatments - August 29th, 2014
- Stem Cell FAQs - MED - Stem Cell Institute, University of ... - August 22nd, 2014
- Home - MED - Stem Cell Institute, University of Minnesota - August 22nd, 2014
- Stem cells | Health Sciences - University of Minnesota - August 22nd, 2014